Pomegra
Haleon Stock Plunges 14% to 52-Week Low After Guidance Cut
Why is Haleon stock down today?
Haleon (HLN) stock fell 14% on Thursday to a 52-week low near $8.57 after the company cut its 2026 sales growth target to about 2.5% on weak cold and flu demand.
Key numbers
| HLN share price (NYSE) | $8.57-14.3% on the day |
|---|---|
| 2026 organic sales growth target | ~2.5%was 3%-5%; one outlet says 3.4% (per [5]) |
| Q3 organic sales growth | 2.6%vs 3.2% expected |
| Respiratory health sales, Q3 | -2.0%organic, year on year |
| Oral health sales, Q3 | +8.8%organic, year on year |
| Brazil hit to Q4 sales | £15M-£20Mfrom new sales model |
What happened
Haleon (HLN) stock fell 14% on Thursday to a 52-week low near $8.57 after the company cut its 2026 sales growth target to about 2.5% on weak cold and flu demand. Third-quarter sales grew 2.6% from a year earlier, below the 3.2% analysts expected, as fewer people bought cough, cold and flu medicines. In China, Haleon had to stop shipping Centrum vitamins after a raw material was reclassified, and a sales-model change in Brazil will cut fourth-quarter sales by £15 million to £20 million. The old target was growth of 3% to 5%.
Why it matters
Haleon, the maker of Sensodyne toothpaste, Advil painkillers and Centrum vitamins, has shown how much its sales depend on a busy cold and flu season. Slower growth in North America, its biggest market, made investors rethink what the company is worth. Haleon still expects profit to grow by a high single-digit percentage and is putting another £500 million into buying back its own shares, so the problem is slower sales rather than falling profit.
Who this affects
- MarketbearishLow impact
- Investors in consumer health stocks turn more cautious, though no wider sell-off.
- CompanybearishHigh impact
- Shareholders took a sharp loss; sales growth now slower than planned.
- CompetitorsneutralLow impact
- Reckitt and Kenvue edged up; rivals saw no sell-off.
- IndustrymixedMedium impact
- Weak flu season hurts cold-medicine makers; oral care stays strong.
Haleon vs Reckitt, Kenvue, Procter & Gamble
How we got here
Haleon's third quarter ends with organic sales up 2.6%, below the 3.2% analysts expected.
Haleon cuts its 2026 sales growth outlook to about 2.5% from 3%-5% and adds a £500M buyback.
Shares fall as much as 17% during the day; US-listed shares hit a 52-week low.
What to watch
- Whether Centrum imports to China restart; the company sees no short-term fix.Q4 2026
- Brazil sales-model change, expected to trim £15M-£20M from fourth-quarter revenue.Q4 2026
- Full-year results, due with the £500M buyback set to finish by then.February 2027
Educational content only. Not investment advice.
More briefsAll briefs →
US GDP Grows 3.4% in Q3 as AI Investment Surges
Q3 GDP beat forecasts as September PCE inflation rose to 3.6% year over year, with core at 3.1%.
DoorDash Stock Jumps 9% Premarket After Instacart Deal
DoorDash (DASH) will pay $65 a share, a 26% premium, to buy Instacart in a $17 billion cash-and-stock deal.
Oil Slips 1.1% to $114 on Hormuz Mine Reports
Brent crude (BZ=F) eased from $115.32 as Iran's Guards reported more tanker mine hits and a $150 oil threat.